Cognition Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is CGTX moving today?
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CGTX.
CGTX insider activity
Cognition Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for CGTX.
CGTX contract awards, year to date.
Public federal awards linked to this ticker.
CGTX lobbying filings, year to date.
Registered lobbying filings matched to Cognition Therapeutics, Inc. Common Stock.